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https://doi.org/10.1016/j.jaci.2020.12.001eczema severity and activity. For example, patients with severe
atopic eczema had a 62% increased hazard (hazard ratio 5
1.62; 99% CI 5 1.54-1.71) for mortality compared with those
without eczema, with the strongest associations for infectious,
respiratory, and genitourinary causes.
Conclusion: The increased hazards for all-cause and cause-
specific mortality were largely restricted to those with the most
severe or predominantly active atopic eczema. Understanding
the reasons for these increased hazards for mortality is an
urgent priority. (J Allergy Clin Immunol 2020;nnn:nnn-nnn.)
Key words: Activity, atopic eczema, cohort study, electronic health
care records, mortality, population-based, primary care, severity,
United Kingdom
Atopic eczema affects up to 10% of adults1 and is becoming
more common globally.2 It is a challenging disease characterized
by itch, sleeplessness, and adverse effects on quality of life.
Approximately 30% of people with atopic eczema have
moderate-to-severe disease.3-5
Recent evidence has led to a paradigm shift in how atopic
eczema is perceived, from focusing on skin symptoms and
associated allergic diseases to understanding that atopic eczema
may be associated with a range of important medical outcomes.
For example, we have previously examined the association
between atopic eczema and cardiovascular outcomes, including
cardiovascular death.6 A recent meta-analysis of the limited evi-
dence base in this area that was conducted by our group found
atopic eczema to be associated with an increased risk of myocar-
dial infarction, ischemic stroke, angina, and heart failure in the
identified cohort studies, although the analysis did not find any ev-
idence for pooled associations with angina, myocardial infarc-
tion, heart failure, or stroke from cross-sectional studies.7
Few studies have assessed whether atopic eczema increases the
risk of death. Danish data suggest that atopic eczema might be
associated with a slightly increased risk of death in people
hospitalizedwith atopic eczema and people diagnosedwith atopic
eczema in outpatient hospital speciality clinics.8,9 However,
limited sample sizes and poor information on potential mediators
hamper conclusions. Atopic eczema is a relapsing and remitting
disease that varies in severity and disease activity, but no study
has examined whether the potential association between atopic
eczema and mortality differs in terms of these characteristics. If
atopic eczema is associated with increased mortality, this is
important from both a public health and a therapeutic perspective,
as atopic eczema is common in adults.1
Therefore, our objective was to examine whether adults with
atopic eczema had greater all-cause and cause-specific mortality
rates than adults without atopic eczema in a UK general popu-
lation cohort. We also aimed to investigate whether the all-cause1
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severity and disease activity over time.METHODS
Study design and setting
We undertook a cohort study using data from the UK Clinical Practice
Research Datalink (CPRD) that were linked to Hospital Episode Statistics
(HES) inpatient data, Office for National Statistics (ONS) mortality data, and
Index of Multiple Deprivation (IMD) data. CPRD is a database of prospec-
tively collected primary care records from general practitioners (GPs) that
were collected by using Vision software; approximately 7% of the UK
population are represented in the database.10,11 Approximately 80% of CPRD
practices registered in England have consented to their patients’ primary care
records being linked to other data sources. HES records include all National
Health Service–funded inpatient hospitalizations in England since 1997,
including diagnoses and procedures. ONS-linked mortality data contain the
underlying cause of death, recorded on the death certificate, along with up
to 15 other recorded causes of death. IMD is an area-level measure of relative
deprivation. For this study, datawere extracted from the July 2017CPRDbuild
and the Set 14–linked data. All code lists are available on the London School
of Hygiene and Tropical Medicine Data Compass website (https://doi.org/10.
17037/DATA.00001986).Study population
All adults (aged >_18 years) contributing to CPRD between January 2, 1998,
and March 31, 2016, with linked HES and ONS mortality data were eligible
for inclusion. All individuals had to be registered with a practice meeting
CPRD quality control standards and have at least 12 months of registration
before study entry (to allow adequate time for recording of covariate data in
the patient record).
Defining patients with atopic eczema and matched
unexposed individuals. The exposed cohort included all patients
with atopic eczema, with onset defined at the latest of an atopic eczema
diagnosis and 2 atopic eczema treatments (on separate dates), which is
consistent with a validation study demonstrating a positive predictive value in
adults of 82% (95% CI5 73%-89%)12 (see Methods E1 in the Online Repos-
itory at www.jacionline.org). For each patient with atopic eczema, we
randomly matched without replacement up to 5 individuals without eczema
by age (within 15 years), sex, and general practice (see Methods E1).
A graphic depiction of the study design is presented in Fig E1 (in the Online
Repository at www.jacionline.org).Defining follow-up
Follow-up for exposed patients began at the latest of the following dates:
January 2, 1998; the date on which the individual turned 18 years old; the date
on which the individual fulfilled our diagnostic algorithm for atopic eczema
(ie, the latest of a record of a diagnostic morbidity code for eczema or the
second record for eczema therapy), and the start of CPRD follow-up plus 365
days. Follow-up for unexposed individuals began at the start date of their
matched patient with atopic eczema. Follow-up ended at the earliest of studyend date, death (using the ONS date), transfer out of practice, or practice last
collection date. Patients contributing at least 1 day of follow-up were included
in the study.Defining eczema severity and activity
Atopic eczema severity was defined as a time-updated variable for patients
with atopic eczema so that at any given point during follow-up they belonged
to 1 of 3 severity categories: mild, moderate, or severe (see Methods E1).
Atopic eczema activity was characterized by using the first 12 months of
follow-up, with patients with atopic eczema split into 3 categories for analysis:
those who never had active atopic eczema during the first year of follow-up,
those who had active atopic eczema for less than 50% of the first year of
follow-up, and those who had active atopic eczema for at least 50% of the first
year of follow-up (see Methods E1). This was a post hoc analysis, as results
from our prespecified analysis were suggestive of time-related bias (see
Methods E2 in the Online Repository at www.jacionline.org).Defining mortality outcomes
Mortality was considered separately by underlying cause of death (in-
fections [International Classification of Diseases, 10th Revision (ICD-10)
Chapter I], neoplasms [ICD-10Chapter II], circulatory disease [ICD-10Chap-
ter IX], respiratory disease [ICD-10 Chapter X], digestive disease [ICD-10
Chapter XI], diseases of the genitourinary system [ICD-10 Chapter XIV],
and other causes [all other ICD-10 chapters]), as well as by all causes com-
bined. Deaths from each cause were identified from ONS data, defined as
any relevant ICD-10 (2001 onward) or International Classification of Dis-
eases, Ninth Revision (before 2001) code recorded as a cause of death.Covariates
Weused a directed acyclic graph13 to inform the identification of covariates
and avoid collider bias (see Fig E2 in the Online Repository at www.
jacionline.org). We considered variables relating to calendar period, sex, so-
cioeconomic deprivation (IMD), ethnicity, and age as potential confounders
to be adjusted for in analyses. Full details regarding the definition of these vari-
ables can be found in Methods E1.Statistical analysis
The characteristics of those with and without atopic eczema (at cohort
entry) were described. We estimated the cause-specific cumulative incidence
functions in the atopic eczema–exposed patients only on account of the fact
that because of the matching, atopic eczema–unexposed patients in the sample
are not representative of the population of eczema-unexposed patients. For
each cause of death, we estimated the cumulative incidence function in the
full sample of exposed patients nonparametrically, allowing for competing
risks.14
Primary analyses. For both the all-cause and cause-specific mor-
tality analyses, we used Cox regression stratified by matched set (matched on
age at cohort entry, sex, and practice) with current age as the underlying time
scale to estimate hazard ratios (HRs) for the association between atopic
eczema and mortality (the ‘‘unadjusted’’ model). A subsequent multivariable
analysis adjusted for a priori confounders (current calendar period, IMD, and
time-varying asthma [the ‘‘adjusted’’ model]). We used 99% CIs and an
implied 1% level of statistical significance to reduce the risk of type 1 error,
consistent with CPRD Independent Scientific Advisory Committee
guidelines.
All-cause and cause-specific mortality incidence rates in the atopic
eczema–exposed patients were estimated by using the data in our sample.
Incidence rates among people without atopic eczema (which cannot be
reliably estimated from the sample on account of the matching) were then
estimated by multiplying the incidence rate in the atopic eczema–exposed
patients by our corresponding estimated HR (after having first inverted it so
that it compared unexposed patients with exposed patients). Attributable risks
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incidence rates. Population-attributable risks were estimated by using the
estimated HR and assuming an atopic eczema prevalence of 10%.15
Secondary analyses. We repeated analyses (adjusted model only)
within strata of sex, current asthma status, and current age group (18-39, 40-
59, and >_60 years) to explore potential effect modification. We also repeated
the analysis with alternative exposure definitions, where atopic eczema was
categorized on the basis of severity and separately, on the basis of category of
disease activity. Finally, we conducted an exploratory mediation analysis that
is described and reported in Methods E3 (in the Online Repository at www.
jacionline.org).
Sensitivity analyses and model checking. A series of
sensitivity analyses were conducted (Table I). We checked the proportional
hazards assumption in all the primary analysis models through plots of the
Sch€oenfeld residuals.
Software. All analyses were conducted using Stata, version 15
(StataCorp, College Station, Tex).RESULTS
In total, 3,094,608 individuals (526,736 patients with atopic
eczema and 2,567,872 unexposed individuals) were successfully
matched and eligible for cohort entry (Fig 1). The median age at
cohort entry was 41.8 years, and the median follow-up was 4.5
years (Table II). Among all the patients with atopic eczema,
5.7% of the total follow-up was spent with severe atopic eczema.
The most common causes of death among the atopic eczema–
exposed patients were circulatory disease and neoplasms, with
infections and diseases of the genitourinary system causing the
fewest deaths (see Fig E3 in the Online Repository at www.
jacionline.org). The median age at death among the atopic
eczema–exposed patients was 83.2 years.
In the primary analysis, there was limited evidence of an
association between atopic eczema and all-causemortality (HR5
1.04; 99% CI 5 1.03-1.06 in the adjusted model), but there were
somewhat stronger associations with several of the individual
causes of death (Table III). Associations were strongest with in-
fections (HR 5 1.14; 99% CI 5 0.98-1.32), digestive diseases
(HR5 1.11; 99% CI5 1.03-1.19), and diseases of the genitouri-
nary system (HR 5 1.08; 99% CI 5 0.96-1.20).
The estimated attributable risks confirmed the higher incidence
rates of all-cause and cause-specific mortality among those with
atopic eczema, although the absolute levels were relatively
modest (Table IV1,15). The all-cause mortality-attributable risk
was 62 per 100,000 person years (99% CI 5 40-84), and the
cause-specific mortality-attributable risks were greatest for neo-
plasms ( 24 per 100,00 person years; 99% CI5 12-35) and circu-
latory disease (18 per 100,000 person years; 99%CI5 5-31). The
greatest population-attributable risks were estimated for infec-
tions (1.4%; 99% CI 5 –0.2-3.1) and digestive disease ( 1.1%;
99% CI 5 0.3-1.8).
There was no convincing evidence of effect modification by
asthma (see Table E1 in the Online Repository at www.jacionline.
org). However, stronger associations were observed in males and
younger people (aged 18-39 or 40-59 years, depending on the
cause of death) for several causes of death (see Tables E2 and
E3 in the Online Repository at www.jacionline.org).
A total of 34,610 people, contributing 187,910 years of follow-
up time, were classified as having severe atopic eczema, of whom
4,446 died. Associations were substantially stronger in patients
with severe atopic eczema than in those without eczema, in
particular, for deaths due to infections (HR 5 2.85; 99% CI 51.78-4.55 in the adjusted model), respiratory disease (HR5 2.20;
99%CI5 1.91-2.53), diseases of the genitourinary system (HR5
2.10; 99% CI 5 1.43-3.07), and other causes (HR 5 1.91; 99%
CI5 1.66-2.21), as well as for mortality overall (HR5 1.62; 99%
CI5 1.54-1.71) (Fig 2 and see Table E4 in the Online Repository
at www.jacionline.org). Associations were also stronger in people
with the most active atopic eczema (Fig 3 and see Table E5 in the
Online Repository at www.jacionline.org).Sensitivity analyses and model checking
The sensitivity analysis results are presented in Table I.
Sch€oenfeld residual plots did not provide compelling evidence
that the proportional hazards assumption was not satisfied in the
primary analysis models.DISCUSSION
Principal findings
This study found limited evidence of increased all-cause
mortality in those with atopic eczema, although there was a small
increase in the rate of death due to some specific causes. The
differences on the absolute scale were modest owing to the low
overall mortality rates. There was, however, strong evidence of
elevated mortality among patients with the most severe or active
eczema.Comparison with other studies
Two previous studies, both of which used Danish hospital
registry data, assessed whether atopic eczema is associated with
increased mortality.8,9 Egeberg et al assessed mortality during the
10 years following hospital admission for atopic eczema; they re-
ported a 71% increased hazard formortality comparedwith that in
the Danish general population.8 These findings are consistent
with our observation of a 62% increased hazard of death in those
with severe eczema in the UK population. Thyssen et al reported a
27% greater hazard of mortality in people diagnosed with atopic
eczema in outpatient hospital clinics or certain private derma-
tology clinics (moderate) or during hospital admission (severe)
than in people without atopic eczema in the Danish general pop-
ulation.9 As the majority of patients are likely to represent mod-
erate eczema, the findings of Thyssen et al are consistent with the
small increase in rates of death that we observed for those with
moderate atopic eczema.
Thyssen et al9 examined cause-specific mortality, reporting
increased rates of death due to cardiovascular, infectious, and uro-
genital disease, but with very wide CIs, as the sample size was
small (N 5 8,686, with fewer than 10 deaths for most specific
causes). Our study observed similarly increased rates of death
due to these causes, and it additionally found increased rates of
death due to respiratory disease and digestive diseases, particu-
larly in those with the most severe or active atopic eczema.
The finding of increased hazard of death associated with
infectious diseases is supported by previous observations from
our group, and from others, of increased risks of cutaneous and
extracutaneous infections in those with atopic eczema.16,17
Possible mechanisms of this increased risk include skin barrier
and immunologic dysfunction. Use of systemic immunosuppres-
sants is an alternative explanation; however, adjusting for this
covariate in sensitivity analyses did not attenuate the association.
TABLE I. Overview of sensitivity analyses
Sensitivity analysis Justification Findings
Primary analyses
The primary analysis was repeated on an incident
(newly active) atopic eczema cohort (exposed
patients, defined as those joining the cohort
when they first fulfill our diagnostic criteria and
after the start of the study period)
To reduce potential overadjustment, as
covariates measured at entry precede atopic
eczema onset in the incident atopic eczema
cohort so will not be on the causal pathway
between atopic eczema and mortality
Associations were partially attenuated for most
causes of death relative to those in the
primary analysis (see Table E6 in the Online
Repository at www.jacionline.org)
The primary analysis was repeated on individuals
with at least 1 consultation with their GP in the
year before cohort entry
To reduce the possibility that the control group
members are healthier purely because of the
study design (controls are not required to have
had a recent GP consultation in the primary
analysis, whereas atopic eczema is defined on
the basis of diagnosis and relevant treatment)
Associations were partially attenuated for all
causes of death relative to those in the
primary analysis (see Table E7 in the Online
Repository at www.jacionline.org)
The primary analysis was repeated on a first
redefined cohort (‘‘first redefined cohort’’),
where the pool of unexposed persons also
included patients with an atopic eczema diag-
nosis but without 2 further treatments for the
entire duration of their follow-up and patients
in the exposed cohort (with an atopic eczema
diagnosis and 2 further treatments) were
included as unexposed up until their cohort
entry (ie, the latest of their atopic eczema
diagnosis and their 2 further treatments)
To explore the sensitivity of the results to the
definition of the exposure
Associations were very similar to those in the
primary analysis for all causes of death
(see Table E8 in the Online Repository at
www.jacionline.org)
The primary analysis was repeated on a second
redefined cohort (‘‘second redefined cohort’’),
where the exposed patients were those with an
atopic eczema diagnosis only (ie, without
requiring 2 atopic eczema treatments), and
these patients were eligible for the unexposed
cohort up until their atopic eczema diagnosis
(some patients may have had childhood atopic
eczema but may not have had treatment codes
recorded if registered at GP during adulthood,
and therefore may have been erroneously
excluded from the exposed cohort in the
primary analysis)
To explore the sensitivity of the results to the
definition of the exposure
Associations were partially attenuated for all
causes of death relative to those in the
primary analysis (see Table E9 in the Online
Repository at www.jacionline.org)
The primary analysis was repeated on a subset of
patients registered from 2006 onward, with
additional adjustment for ethnicity
To examine whether the omission of this
covariate in the primary analysis may have
introduced bias
Associations adjusted for ethnicity (restricting to
the 339,734 people who had such data
available and who remained in valid matched
sets) were consistent with those that were
unadjusted for ethnicity in the same reduced
cohort (see Table E10 in the Online
Repository at www.jacionline.org)
The primary analysis was repeated with the
exposure redefined to represent time-varying
time since diagnosis (unexposed vs exposed at
0-4 years since diagnosis vs exposed at 5-9
years since diagnosis vs exposed at >_10 years
since diagnosis)
To examine whether the association between
atopic eczema and all-cause and cause-
specific mortality differed by time since
diagnosis
The association with all-cause mortality
appeared less strong within 5 years of
diagnosis than it was more than 5 years after
diagnosis, but the patterns with individual
causes of death were heterogeneous (see
Table E11 in
the Online Repository at www.jacionline.
org)
Secondary analyses
The atopic eczema severity analysis was repeated
on individuals with at least 1 consultation with
their GP in the year before cohort entry
To reduce the possibility that the control group
members were healthier purely owing to the
study design (controls were not required to
have had a recent GP consultation in the
primary analysis, whereas atopic eczema was
defined on the basis of diagnosis and relevant
treatment)
Associations were only slightly attenuated
relative to those in the unrestricted analysis
(see Table E12 in the Online Repository
at www.jacionline.org)
(Continued)
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TABLE I. (Continued)
Sensitivity analysis Justification Findings
The atopic eczema activity analysis was repeated
on individuals with at least 1 consultation with
their GP in the year before cohort entry
To reduce the possibility that the control group
was healthier purely on account of to the
study design (controls were not required to
have had a recent GP consultation in the
primary analysis, whereas atopic eczema was
defined on the basis of diagnosis and relevant
treatment)
Associations were only slightly attenuated
relative to those in the unrestricted analysis
(see Table E13 in the Online Repository at
www.jacionline.org)
The atopic eczema activity analysis (assessed
during the first 12 months of follow-up,
assuming active eczema for 3 months after a
single health care contact) was repeated,
without excluding the first year of follow-up
To explore any potential bias caused by
conditioning on survival up to 12 months in
the analysis in which the first 12 months of
follow-up are excluded. However, bias due to
inclusion of the exposure definition period in
follow-up may instead be induced
Associations were generally very similar,
although with greater evidence of a protective
association with moderately active atopic
eczema for some causes of death (see Table
E14 in the Online Repository at www.
jacionline.org)
FIG 1. Data flowchart for UK population–based cohort study, 1998–2016.
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TABLE II. Summary statistics for individuals included in the study
Characteristic
Without atopic eczema
n 5 2,567,872 (83.0%)
With atopic eczema
n 5 526,736 (17.0%) Total N 5 3,094,608
Follow-up (y), median (first and third quartiles) 4.4 (1.7, 8.9) 5.0 (2.0, 9.6) 4.5 (1.7, 9.0)
At entry into cohort
Sex, no. (%)
Male 1,079,198 (42.0) 218,702 (41.5) 1,297,900 (41.9)
Female 1,488,674 (58.0) 308,034 (58.5) 1,796,708 (58.1)
Age (y), median (first and third quartiles), no. (%) 41.7 (27.0, 60.8) 42.3 (25.7, 62.3) 41.8 (26.7, 61.1)
18-19 317,332 (12.4) 81,760 (15.5) 399,092 (12.9)
20-29 471,212 (18.4) 84,511 (16.0) 555,723 (18.0)
30-39 429,028 (16.7) 80,315 (15.2) 509,343 (16.5)
40-49 351,880 (13.7) 69,694 (13.2) 421,574 (13.6)
50-59 328,941 (12.8) 63,942 (12.1) 392,883 (12.7)
60-69 303,674 (11.8) 61,896 (11.8) 365,570 (11.8)
70-79 227,150 (8.8) 52,037 (9.9) 279,187 (9.0)
>_80 138,655 (5.4) 32,581 (6.2) 171,236 (5.5)
IMD, no. (%)
1 (least deprived) 611,696 (23.8) 126,788 (24.1) 738,484 (23.9)
2 589,085 (22.9) 120,936 (23.0) 710,021 (22.9)
3 508,244 (19.8) 103,632 (19.7) 611,876 (19.8)
4 488,876 (19.0) 100,415 (19.1) 589,291 (19.0)
5 (most deprived) 369,971 (14.4) 74,965 (14.2) 444,936 (14.4)
BMI, no. (%)
Underweight 65,917 (3.2) 13,442 (3.0) 79,359 (3.1)
Normal weight 947,898 (45.7) 196,737 (44.1) 1,144,635 (45.4)
Overweight 667,042 (32.2) 143,901 (32.2) 810,943 (32.2)
Obese 393,485 (19.0) 92,520 (20.7) 486,005 (19.3)
Smoking, no. (%)
Nonsmoker 1,293,562 (53.5) 266,116 (51.9) 1,559,678 (53.2)
Current/ex-smoker 1,125,203 (46.5) 246,748 (48.1) 1,371,951 (46.8)
Diabetes, no. (%) 127,484 (5.0) 32,387 (6.1) 159,871 (5.2)
Depression, no. (%) 53,619 (2.1) 15,382 (2.9) 69,001 (2.2)
Anxiety, no. (%) 18,577 (0.7) 5,941 (1.1) 24,518 (0.8)
Asthma, no. (%) 318,263 (12.4) 125,815 (23.9) 444,078 (14.4)
Severe alcohol use, no. (%) 57,215 (2.2) 14,351 (2.7) 71,566 (2.3)
By exit from cohort, no. (%)
Diabetes 233,623 (9.1) 59,922 (11.4) 293,545 (9.5)
Depression 107,424 (4.2) 31,018 (5.9) 138,442 (4.5)
Anxiety 33,302 (1.3) 10,067 (1.9) 43,369 (1.4)
Asthma 385,700 (15.0) 146,179 (27.8) 531,879 (17.2)
Severe alcohol use 86,306 (3.4) 21,794 (4.1) 108,100 (3.5)
BMI, Body mass index; GUS, genitourinary system.
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those with the most severe or active atopic eczema is consistent
with reports from our group and others.6 Of note, the findings
regarding circulatory disease mortality in this article do not
exactly duplicate those for cardiovascular death in our previous
work owing to differing exclusion criteria and outcome defini-
tions (leading to mortality rates in eczema-unexposed individuals
of 319 and 460 per 100,000 person years, respectively).6 Mecha-
nisms for the increased risk may include reduced physical actv-
ity18 and reduced sleep quality.19
Our observation of a 2-fold increase in hazard of mortality
among those with severe atopic eczema related to urogenital
disease highlights an area that requires more research. Previous
limited reports have suggested that children with atopic eczema
may have an increased risk of nephrotic syndrome.20-23 Use of
cyclosporine for severe atopic eczema could lead to an increased
risk of chronic kidney disease, although similar estimates were
seen in our study when adjusting, albeit fairly crudely, for use
of systemic treatment for atopic eczema. Increased risks ofchronic kidney disease have also been observed in other inflam-
matory dermatoses such as psoriasis.24-26 Understanding of these
associations is currently limited; the proposed mechanisms
include increased prevalence of metabolic syndrome and cardio-
vascular disease, use of nephrotoxic drugs, or relationship to
chronic inflammation over many years.27
The increasedmortality due to respiratory diseasemay relate to
residual confounding on account of misclassification of asthma.
Alternative explanations could be adverse effects of drugs (eg,
azathioprine) or residual confounding from smoking.
Our observation of increased mortality due to digestive
diseases is novel and warrants replication and further analyses.
Atopic eczema is known to be associated with eosinophilic
esophagitis, but there are limited studies addressing potential
gastrointestinal diseases that might increase mortality risk, such
as peptic ulceration. Alternative explanations may include
adverse effects of drugs or residual confounding from alcohol use.
The observation that associations between atopic eczema and
mortality (on a relative scale) were highest in younger individuals
TABLE III. Association between eczema and all-cause and cause-specific mortality (cause-specific hazards) (N 5 3,094,608)
Mortality n P-Y at risk Events
HR and 99% CI*
Unadjusted Adjusted
All-cause mortality
Unexposed 2,567,872 14,925,990 199,645 1.00 (ref) 1.00 (ref)
Exposed 526,736 3,308,778 49,514 1.08 1.06, 1.09 1.04 1.03, 1.06
Cause-specific mortality
Infections
Unexposed 2,567,872 14,925,990 2,040 1.00 (ref) 1.00 (ref)
Exposed 526,736 3,308,778 563 1.17 1.01, 1.36 1.14 0.98, 1.32
Neoplasms
Unexposed 2,567,872 14,925,990 56,873 1.00 (ref) 1.00 (ref)
Exposed 526,736 3,308,778 14,052 1.08 1.05, 1.11 1.06 1.03, 1.09
Circulatory disease
Unexposed 2,567,872 14,925,990 68,669 1.00 (ref) 1.00 (ref)
Exposed 526,736 3,308,778 16,788 1.06 1.03, 1.09 1.04 1.01, 1.06
Respiratory disease
Unexposed 2,567,872 14,925,990 28,383 1.00 (ref) 1.00 (ref)
Exposed 526,736 3,308,778 7,670 1.17 1.12, 1.22 1.06 1.02, 1.11
Digestive disease
Unexposed 2,567,872 14,925,990 9,492 1.00 (ref) 1.00 (ref)
Exposed 526,736 3,308,778 2,451 1.14 1.07, 1.22 1.11 1.03, 1.19
Diseases of the GUS
Unexposed 2,567,872 14,925,990 3,877 1.00 (ref) 1.00 (ref)
Exposed 526,736 3,308,778 1,008 1.10 0.98, 1.23 1.08 0.96, 1.20
Other causes
Unexposed 2,567,872 14,925,990 30,311 1.00 (ref) 1.00 (ref)
Exposed 526,736 3,308,778 6,982 1.00 0.96, 1.04 0.99 0.95, 1.03
GUS, Genitourinary system; P-Y, person years; ref, reference.
Unadjusted means no adjustment; adjusted means adjusted for the current calendar period (1998-2001, 2002-2004, 2005-2007, 2008-2010, 2011-2013, and 2014-2016), Index of
Multiple Deprivation at cohort entry and time-varying asthma.
*Estimated HRs from Cox regression with current age as the underlying time scale, stratified by matched set (matched on age at cohort entry, sex, date at cohort entry, and
practice).






























risk (%) and 99% CIk
All-cause mortality 1496 1.04 1.03-1.06 0.96 0.94-0.97 1435 1413-1457 62 40-84 0.4 0.3-0.6
Cause-specific mortality
Infections 17 1.14 0.98-1.32 0.88 0.76-1.02 15 13-17 2 0-4 1.4 –0.2-3.1
Neoplasms 425 1.06 1.03-1.09 0.94 0.92-0.97 401 390-412 24 12-35 0.6 0.3-0.9
Circulatory disease 507 1.04 1.01-1.06 0.96 0.94-0.99 490 477-503 18 5-31 0.4 0.1-0.6
Respiratory disease 232 1.06 1.02-1.11 0.94 0.90-0.98 218 209-228 14 4-23 0.6 0.2-1.1
Digestive disease 74 1.11 1.03-1.19 0.90 0.84-0.97 67 62-72 7 2-12 1.1 0.3-1.8
Diseases of the GUS 30 1.08 0.96-1.20 0.93 0.83-1.04 28 25-32 2 –1-5 0.7 –0.4-2.0
Other causes 211 0.99 0.95-1.03 1.01 0.97-1.05 213 204-222 -2 –11-7 –0.1 –0.5-0.3
*Comparison of atopic eczema–exposed patients with people without atopic eczema. Estimated HRs from Cox regression with current age as underlying time scale, stratified by
matched set (matched on age at cohort entry, sex, date at cohort entry, and practice) comparing atopic eczema–exposed people with atopic eczema–unexposed people. Adjusted for
current calendar period (1998-2001, 2002-2004, 2005-2007, 2008-2010, 2011-2013, and 2014-2016), Index of Multiple Deprivation quintile at cohort entry, and time-varying
asthma.
Comparison of people without atopic eczema with atopic eczema–exposed patients.
Calculated by multiplying the estimated incidence rate in atopic eczema–exposed patients by the inverse estimated HR and 99% CI.
§Calculated by subtracting the estimated incidence rate and 99% CI in people without atopic eczema from the estimated incidence rate in atopic eczema–exposed patients.
kEstimated as P(HR – 1)/(1 1 P(HR – 1)), where P (the prevalence of atopic eczema) is assumed to be 10%1,15 and HR is the estimated HR comparing atopic eczema–exposed
patients with people without atopic eczema.
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*vs. no eczema .8 1 1.5 2 3 4
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Unadjusted
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Adjusted
FIG 2. Association between atopic eczema and all-cause and cause-specific mortality, by severity of atopic
eczema (n 5 3,094,608). Estimated cause-specific HRs from Cox regression with current age as underlying
time scale, stratified bymatched set (matched on age at cohort entry, sex, date at cohort entry, and practice).
Unadjusted means no adjustment; adjusted means adjusted for the current calendar period (1998-2001,
2002-2004, 2005-2007, 2008-2010, 2011-2013, and 2014-2016), Index of Multiple Deprivation at cohort entry,
and time-varying asthma. GUS, Genitourinary system.
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8 SILVERWOOD ET ALfor most causes of death may be explained by younger people
being relatively less likely to die of most causes regardless of their
atopic eczema status, meaning that there was greater opportunity
for a raised HR, which is consistent with the findings of other
studies of inflammatory skin diseases.28
We chose not to look specifically at death due to suicide over
concerns regarding the reliability of coding for this cause of
death. However, patients with atopic eczema have been found to
be at increased risk of suicidal ideation and suicide attempts,29 so
suicide may be contributing to the observed increased hazard of
death due to ‘‘other causes’’ among those with the most severe
or active atopic eczema.Strengths and limitations
This study is, to our knowledge, the largest study to date to
assess the association between atopic eczema and all-cause and
cause-specific mortality.We used population-based data fromUK
general practice with linked data on hospitalization and cause-
specific mortality.30,31 Previous studies have demonstrated that
this population is largely representative of the general UK popu-
lation.11We used a validated algorithm to identify atopic eczema,
and our approach to defining atopic eczema severity demonstrated
a distribution of severity similar to that in the publishedliterature.12,32 We used a directed acyclic graph13 to inform the
identification of covariates and avoid collider bias. The primary
analysis included all successfully matched individuals.
Limitations of the study include the possibility for confound-
ing, information bias, and selection bias because of missing data.
It is not possible to disentangle the effects of therapy and severity,
as thosewith more severe disease are given specific therapies. It is
also not possible to truly disentangle the effects of atopic and
nonatopic eczema, as these data do not contain total or specific
IgE levels. ONS mortality data contain the underlying cause of
death as certified by a doctor or a coroner. Although extensive
validation checks are built into the process,33 imprecisions may
remain. However, we would not expect any misclassification of
cause of death to be differential with respect to atopic eczema
diagnosis. Although the algorithm used to identify patients with
atopic eczema was demonstrated to have a positive predictive
value of 82% (95% CI 5 73%-89%) in a previous validation
study,12 there remains the possibility of misclassification of indi-
viduals with atopic eczema, which may have led to bias.
People were matched within 15-year age intervals, as finer age
matching led to a significant loss of thosewith atopic eczemawith
no eligible matches. However, age was accounted for as the
underlying time scale in all analyses, closely adjusting for the



































*vs. no eczema .6 .8 1 1.5 2
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FIG 3. Association between atopic eczema and all-cause and cause-specific mortality, by activity of atopic
eczema (assessed during the first 12 months of follow-up, assuming active eczema for 3 months after a
single health care contact), excluding the first 12 months of follow-up (n 5 2,614,344). Estimated cause-
specific HRs from Cox regression with current age as underlying time scale, stratified by matched set
(matched on age at cohort entry, sex, date at cohort entry, and practice). Unadjusted means no adjustment;
adjustedmeans adjusted for the current calendar period (1998-2001, 2002-2004, 2005-2007, 2008-2010, 2011-
2013, and 2014-2016), Index of Multiple Deprivation at cohort entry, and time-varying asthma. GUS, Geni-
tourinary system.
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SILVERWOOD ET AL 9the early years of the study period meant that ethnicity could not
be included in the main analyses, the results adjusted for ethnicity
in the subsample with complete data were consistent with those
from the primary analysis conducted on the same reduced cohort,
suggesting limited bias from omission of this covariate.
Individuals with worse health are more likely to see their GP,
and given that our algorithm used to identify patients with atopic
eczema required a GP visit whereas visiting aGPwas not required
in our comparison cohort, there is the potential for overestimation
of the relative mortality risk among patients with atopic eczema.
Although there was some evidence of this in the sensitivity
analysis restricting the primary analysis to individuals with at
least 1 consultation with their GP in the year before cohort entry,
in the equivalent atopic eczema severity and activity analyses
there remained strong evidence of increased mortality in those
with the most severe or active eczema, suggesting that such bias
was not the cause of the observed findings.
Assessing major long-term health outcomes in a disorder such
as atopic eczema that frequently starts in early childhood may be
challenging owing to possible survival bias.34,35 As survival bias
would bias the association toward the null, it cannot explain our
findings, and it could potentially have led to underestimation ofthe associations.36 Onset confounding (differential time since
atopic eczema onset) may bias the results, although the direction
of bias will depend on whether the rate of mortality increases or
decreases with time since onset. The attenuation of results for
most causes of death when restricting to incident atopic eczema
diagnoses suggests that such bias may be present to some degree,
although interpretation is difficult given the possibility ofmisclas-
sification of preexisting (childhood) eczema as incident (adult-
hood) eczema.
Misclassification of disease severity is possible (for example,
when examining whether patients with severe disease used only
topical treatment or patients requiring systemic therapies subse-
quently went into ‘‘remission’’ or had predominantly mild
disease). Although the atopic eczema severity and activity aspects
of the algorithm are unvalidated and based on clinical judgment,
the proportions of individuals in each group are consistent with
those in previous reports.37
Although we used 99% CIs and an implied 1% level of
statistical significance to reduce the risk of type 1 error in the
primary analyses, the total number of analyses undertaken (ie,
those including sensitivity analyses) means that type 1 errors
remain a possibility.
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10 SILVERWOOD ET ALConclusions
We have shown a small increase in the rate of mortality due to
several causes in individuals with atopic eczema. This increased
risk is particularly elevated in individuals with severe or more
active disease. People with severe atopic eczema warrant
thorough health assessments, including preventative approaches.
Useful next steps would be to improve our understanding of the
likely causes of these increased hazards for mortality in severe or
predominantly active atopic eczema and whether proactive
reduction in inflammation with systemic treatments can decrease
overall and cause-specific mortality.
This work uses data provided by patients and collected by theNHS as part of
their care and support.
Key messages
d Our study found a small increased hazard for mortality
due to several causes in those with atopic eczema.
d Patients with severe and predominantly active atopic
eczema were found to have an increased hazard for all-
cause mortality compared with those without eczema.
d The excess risk of death in patients with severe atopic
eczema was highest for deaths due to infections, respira-
tory disease, and diseases of the genitourinary system.REFERENCES
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